2026-04-13T05:51:31Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1336812025-12-05T09:20:32Zcom_2072_1057col_2072_478799col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Pérez Salvia, Montserrat author Aldaba, Eneko author Vara, Yosu author Fabre, Myriam author Ferrer, Cristina author Masdeu, Carme author Zubia, Aizpea author San Sebastian, Eider author Otaegui, Dorleta author Llinàs-Arias, Pere author Rosselló-Tortella, Margalida author Berdasco, María author Moutinho, Cátia author Setién, Fernando author Villanueva Garatachea, Alberto author González Barca, Eva author Muncunill, Josep author Navarro, José-Tomás author Piris, Miguel A. author Cossio, Fernando P. author Esteller, Manel author 2019-05-22T09:44:06Z 2019-05-22T09:44:06Z 2018-11 2019-05-22T09:44:06Z Cancer origin and development is associated not only with genetic alterations, but also with the disturbance of epigenetic profiles.1 In this regard, the tumoral epigenome is characterized by both specific and general shifts in the DNA methylation and histone-modification landscapes.1 However, in contrast to genetic disruption, the effect of epigenetic modifications or marks may potentially be reversed by the use of drugs that target enzymes involved in adding, removing or signaling DNA methylation and histone modifications.1 This basic knowledge has been adopted into clinical practice, and inhibitors of histone deacetylases and DNA demethylating agents have been approved for use in the therapy of hematologic malignancies, such as cutaneous T-cell lymphoma and myelodysplastic syndrome, respectively.2 Other promising epigenetic drugs include inhibitors of histone methyltransferases,2 histone demethylases,2 histone kinases,3 and bromodomain proteins that interfere with the 'reading' of acetylated histone residues. Inhibidors enzimàtics Histones Cèl·lules T Limfomes Epigenètica Enzyme inhibitors Histones T cells Lymphomas Epigenetics In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma